Adoptive cell therapies, such as CAR T cells, leverage the patient’s immune system to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. To ensure safe and consistent cell therapy products, researchers and manufacturers must develop reproducible workflows and monitor their therapy’s ex vivo potency at several points throughout discovery, process development, manufacturing processes, and manufacturing QC.
Download this ebook from Agilent to discover
- How scientists develop CAR T cell therapy to target cancer cells
- Strategies for overcoming common challenges during CAR T cell development
- How researchers determine CAR T cell potency with xCELLigence Real-Time Cell Analysis (RCTA)
- Automated manufacturing workflows for safe and efficacious cell-based therapy development
